Clinical Trials Browser

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06201507 2024-01-12

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Phase 2 Unknown

44 enrolled

Lymphoid

Hodgkin Disease

NCT02398240 2023-10-26

Brentuximab for Newly Diagnosed Hodgkin Disease

Phase 2 Completed

40 enrolled

Lymphoid

Hodgkin Disease

NCT00004197 2023-09-07

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00785798 2022-04-04

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Phase 1/2 Terminated

17 enrolled 4 charts

Lymphoid

Lymphoma

NCT04069845 2021-03-17

A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin

Unknown

2,000 enrolled

Lymphoid

Lymphoma

NCT00101010 2020-10-19

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Phase 2 Completed

80 enrolled 7 charts

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00290433 2020-09-23

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Phase 2 Completed

55 enrolled 5 charts

Lymphoid

Lymphoma

NCT01902225 2020-06-09

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Phase 1 Completed

24 enrolled

DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Phase 2 Terminated

21 enrolled 13 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01887587 2020-01-22

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Phase 1 Terminated

5 enrolled 9 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00392990 2019-10-15

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

Phase 2 Completed

25 enrolled 16 charts

Lymphoid

Burkitt Lymphoma, Lymphoma

NCT03952572 2019-05-16

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Phase 3 Unknown

244 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00837200 2017-07-24

Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Phase 2 Terminated

13 enrolled 12 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Plasma Cell

NCT03023358 2017-01-18

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Phase 3 Unknown

174 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02428751 2015-11-18

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Phase 3 Unknown

216 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01490047 2015-06-16

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Phase 1 Withdrawn

Lymphoid

Lymphoma

NCT00183976 2014-05-22

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Phase 2 Terminated

15 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Primary Effusion

NCT00575406 2013-08-30

NHL-14

Phase 2 Completed

94 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00237627 2012-05-18

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Phase 1/2 Completed

107 enrolled

BreastDermatologicGynecologicLymphoidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Ovarian Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Intraocular Lymphoma

NCT00161239 2009-12-11

LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma

Phase NA Terminated

64 enrolled

Lymphoid

Lymphoma, T-Cell

NCT00141648 2009-10-01

Chemotherapy and Radiotherapy for Osteolymphoma

Phase NA Completed

70 enrolled

Lymphoid

Lymphoma

NCT00946374 2009-07-27

HD-MCL2003

Phase 2 Unknown

20 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00333008 2006-09-26

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Phase 2 Unknown

27 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

LONCA

BV mini CHP

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Brentuximab for Newly Diagnosed Hodgkin Disease

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

NHL-14

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma

Chemotherapy and Radiotherapy for Osteolymphoma

HD-MCL2003

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.